KROS — Keros Therapeutics Share News
0.000.00%
Last trade - 00:00- $223.65m
- -$33.96m
- $244.06m
Keros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Keros Therapeutics Q2 net loss narrows on lower expenses
Brief: Keros Therapeutics - Keith Regnante Resigns As CFO
Keros Therapeutics posts Q1 net loss as license revenue drops
Keros Therapeutics Q4 net loss narrows to $23.5 mln
Brief: Keros Therapeutics Announces Final Results Of Tender Offer
Biopharma company Keros' Q3 net loss narrows on Takeda license revenue
U.S. STOCKS ON THE MOVE-Bank of America, Dollar Tree, Morgan Stanley
U.S. STOCKS ON THE MOVE-Prologis, Winmark, Amphenol
Keros up after acquiring major investors' shares at premium; unveils $194 million buyback plan
Brief: Keros Announces US FDA Orphan Drug Designation Granted To KER-065
Keros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Keros Therapeutics Inc expected to post a loss of $1.13 a share - Earnings Preview
Factbox: Fat, not muscle: Drugmakers in race for next weight-loss breakthrough
Brief: ADAR1 Capital Management Calls For Keros Therapeutics To Return $475 Mln To Stockholders By Q3
Brief: Keros Therapeutics Announces Tropos Topline Data And Corporate Restructuring
Brief: ADAR1 Capital Management - ISS Recommends Withholding Votes From Keros Therapeutics Directors Mary Ann Gray & Alpna Seth At Annual Meeting
Brief: Keros Therapeutics Board Undertaking Formal Review Process To Evaluate Strategic Alternatives
Brief: Keros Therapeutics Strategic Committee Intends To Consider A Comprehensive Range Of Strategic Alternatives